ライフサイエンスコーパス: vesicular stomatitis virus

1 is observed after intranasal challenge with vesicular stomatitis virus.

2 PPRV were able to neutralize RPV-pseudotyped vesicular stomatitis virus.

3 a and IFN-beta, in protection from oncolytic vesicular stomatitis virus.

4 of H1N1, H6N2, and H11N9 IAV strains but not vesicular stomatitis virus.

5 reovirus, HIV-1, human metapneumovirus, and vesicular stomatitis virus.

6 ecting mice from neuropathogenesis caused by vesicular stomatitis virus.

7 ring infection by Listeria monocytogenes and vesicular stomatitis virus.

8 otection from death after CNS infection with vesicular stomatitis virus.

9 vels of RIG-I and resistance to infection by vesicular stomatitis virus.

10 the pseudotypes bearing the glycoprotein of vesicular stomatitis virus.

11 rovide an advantage for host defense against vesicular stomatitis virus.

12 d infectivity assays with BCoV-S-pseudotyped vesicular stomatitis viruses.

13 In this article, we study the polymerase of vesicular stomatitis virus, a member of the rhabdoviruse

14 Vesicular stomatitis virus, a single-stranded RNA virus,

15 d vaccinia virus Ankara, complex adenovirus, vesicular stomatitis virus, alphavirus-based chimeras, a

16 Vesicular stomatitis virus and influenza A virus infecti

17 een after infection of IL-21R(-/-) mice with vesicular stomatitis virus and influenza virus.

18 n response to infection with the RNA viruses vesicular stomatitis virus and Sendai virus and to trans

19 constructs involving viral vectors (such as vesicular stomatitis virus), and antisense compounds dir

20 ruses, including encephalomyocarditis virus, vesicular stomatitis virus, and influenza virus, in susc

21 rabies virus) and heterologous (inactivated vesicular stomatitis virus) antigens and acceptable accu

22 whereas other RNA viruses (Sindbis virus and vesicular stomatitis virus) are not.

23 gion I) of the L protein from a rhabdovirus, vesicular stomatitis virus, at 1.8-A resolution.

24 EBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expre

25 laque-forming units (pfu) of the recombinant vesicular stomatitis virus-based candidate vaccine expre

26 used a vesicular stomatitis virus-based probe to isolate B cell

27 A recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a su

28 observed in phase 1 studies of a recombinant vesicular stomatitis virus-based vaccine expressing a ZE

29 A live, recombinant vesicular stomatitis virus-based vaccine has been deploy

30 by arboviruses, including Sindbis virus and vesicular stomatitis virus, but this innate restriction

31 d RNA virus, including influenza A virus and vesicular stomatitis virus, by a mechanism independent o

32 ved from viral infections with influenza and vesicular stomatitis virus can persist after resolution

33 al RNA-dependent RNA polymerase L protein of vesicular stomatitis virus catalyzes unconventional pre-

34 Using a recombinant vesicular stomatitis virus containing LUJV GP as its sol

35 source antigens are expressed by vaccinia or vesicular stomatitis virus, either as proteasome-liberat

36 We generated a recombinant vesicular stomatitis virus encoding Ebola virus Makona v

37 nuclear cells were infected with recombinant vesicular stomatitis virus encoding EBOV antigens.

38 pressing influenza, measles, Ebola, Lassa or vesicular stomatitis virus envelope glycoproteins enable

39 mal human glia, fibroblasts, or melanocytes, vesicular stomatitis virus evoked robust beta interferon

40 tion activity in vitro against a recombinant vesicular stomatitis virus expressing MACV GPC (VSV-MACV

41 in lungs following intranasal infection with vesicular stomatitis virus expressing OVA and influenza

42 ne of those vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprot

43 ression plasmid followed by infection with a vesicular stomatitis virus expressing the Zaire ebolavir

44 these MAbs to protect from infection with a vesicular stomatitis virus expressing the Zaire ebolavir

45 remaining fully susceptible to X4-tropic and vesicular stomatitis virus G (VSV-G)-pseudotyped viruses

46 transfected secretory membrane glycoprotein, vesicular stomatitis virus G (VSVG) glycoprotein, was re

47 While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) effici

48 pon infection of the Jurkat T-cell line with vesicular stomatitis virus G glycoprotein (VSV-G)-pseudo

49 F) but, surprisingly, not the trafficking of vesicular stomatitis virus G protein (VSV-G) to the cell

50 "Gectosomes," are designed to co-encapsulate vesicular stomatitis virus G protein (VSV-G) with bioact

51 By contrast, secretory traffic of vesicular stomatitis virus G protein, recycling of inter

52 ination with virus-like particles displaying vesicular stomatitis virus G protein, RNAdjuvant promote

53 gradation of SAMHD1 does not rescue HIV-1 or vesicular stomatitis virus G-pseudotyped lentivectors in

54 These trials used vesicular-stomatitis-virus-G protein (VSV-G)-LVs at high

55 hen an alphavirus RNA replicon expresses the vesicular stomatitis virus glycoprotein (VSV G) as the o

56 Forest virus RNA replicons that express the vesicular stomatitis virus glycoprotein (VSV G) has been

57 Vesicular stomatitis virus glycoprotein (VSV-G)-pseudoty

58 hy, we found that augmenting fusion with the vesicular stomatitis virus glycoprotein (VSVG) increased

59 g human GBA to an exosome-anchoring protein: vesicular stomatitis virus glycoprotein (VSVG), we demon

60 related class III fusion proteins, including vesicular stomatitis virus glycoprotein G (VSV-G) or bac

61 -1 envelope (Env) glycoprotein, but not with vesicular stomatitis virus glycoprotein G (VSV-G).

62 uction enhancement with LVs pseudotyped with vesicular stomatitis virus glycoproteins and also with m

63 stricted to retroviruses, as it also acts on vesicular stomatitis virus glycoproteins.

64 Vesicular stomatitis virus has been shown to bud basolat

65 measles virus, influenza A virus, reovirus, vesicular stomatitis virus, human immunodeficiency virus

66 tent antiviral protection against Sendai and vesicular stomatitis virus in a TLR3 and type I IFN rece

67 o-localization with RIG-I and with infecting vesicular stomatitis virus in Cos-7 cells.

68 In previous work, a prototypic recombinant vesicular stomatitis virus Indiana serotype (rVSIV) vect

69 vity of alpha interferon (IFN-alpha) against vesicular stomatitis virus, Indiana serotype (VSV(IND)),

70 wth inhibition, prolonged protection against vesicular stomatitis virus infection and enhanced transc

71 defect early after Listeria monocytogenes or vesicular stomatitis virus infection but comparable cyto

72 uster activates the IFN pathway and inhibits vesicular stomatitis virus infection by directly targeti

73 e switched Ig in response to immunization or vesicular stomatitis virus infection is strongly impaire

74 ce in lymphocytic choriomeningitis virus and vesicular stomatitis virus infection models.

75 with apoptotic triggers such as etoposide or vesicular stomatitis virus infection, but disassemble in

76 osynthetic inhibition during influenza A and vesicular stomatitis virus infection, but not murine hep

77 Using an intranasal vesicular stomatitis virus infection, we demonstrated th

78 ation and to induce apoptosis in response to vesicular stomatitis virus infection.

79 xpression for EmGFP/IL-15 upregulation after vesicular stomatitis virus infection.

80 Here, we define that vesicular stomatitis virus L initiates synthesis via a d

81 nfections with encephalomyocarditis virus or vesicular stomatitis virus led to higher levels of autop

82 ction as an entry inhibitor for JUNV and for vesicular stomatitis virus, lymphocytic choriomeningitis

83 inhibition also occurred in the presence of vesicular stomatitis virus M (matrix) protein, another v

84 tu formation of dsRNA in cells infected with vesicular stomatitis virus, measles virus, influenza A v

85 ADAM15 expression enhanced rhinovirus 16 and vesicular stomatitis virus-mediated proinflammatory cyto

86 rms, methyltransferase-defective recombinant vesicular stomatitis virus (mtdVSV) and a DNA vaccine.

87 es a rational approach to the attenuation of vesicular stomatitis virus neurovirulence.

88 action results were transiently positive for vesicular stomatitis virus nucleoprotein gene and Ebola

89 s, env-minus viruses pseudotyped with HIV-1, vesicular stomatitis virus, or murine leukemia virus Env

90 dary challenges with Listeria monocytogenes, vesicular stomatitis virus, or Vaccinia virus, but dispe

91 Among vaccines, only the vesicular stomatitis virus platform has been successful

92 and no impact on antibody neutralization of vesicular stomatitis virus pseudotyped with Ebola virus

93 on virus entry or coreceptor expression, as vesicular stomatitis virus-pseudotyped HIV-1 replication

94 V virus-like particle, and EBOV glycoprotein/vesicular stomatitis virus pseudovirion.

95 Using vesicular stomatitis virus pseudovirions bearing EBOV gl

96 ion conferred by an EBOV vaccine composed of vesicular stomatitis virus pseudovirions that lack nativ

97 sponses than UV-inactivated cytomegalovirus, vesicular stomatitis virus, reovirus, or adenovirus.

98 esis and shows reduced capability to control vesicular stomatitis virus replication and to induce apo

99 by IFN in both glioma and melanoma, whereas vesicular stomatitis virus replication was blocked.

100 d-induced interferon production and enhanced vesicular stomatitis virus replication.

101 ession of HAP2 on the surface of pseudotyped vesicular stomatitis virus results in homotypic virus-ce

102 proteins from La Crosse orthobunyavirus and vesicular stomatitis virus reveal insights into RNA synt

103 lescents and 35% of children had recombinant vesicular stomatitis virus RNA detectable in saliva.

104 By in situ analyses of vesicular stomatitis virus RNA synthesis, specific activ

105 The recombinant vesicular stomatitis virus (rVSV) Ebola vaccine was show

106 Recently, we demonstrated that recombinant vesicular stomatitis virus (rVSV) expressing human NoV c

107 ough not licensed for human use, recombinant vesicular stomatitis virus (rVSV) expressing the filovir

108 Previously, recombinant vesicular stomatitis virus (rVSV) pseudotypes expressing

109 onstrated clinical efficacy of a recombinant vesicular stomatitis virus (rVSV) vaccine vector has sti

110 athology after immunization with recombinant vesicular stomatitis virus (rVSV) vaccine vectors, and i

111 ion of VesiculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing fil

112 Recombinant vesicular stomatitis virus (rVSV) was shown to be a high

113 icacy testing of live attenuated recombinant vesicular stomatitis virus (rVSV)-based filovirus vaccin

114 tenuated, replication-competent, recombinant vesicular stomatitis virus (rVSV)-based vaccine candidat

115 The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressi

116 approaches is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressi

117 Monovalent recombinant vesicular stomatitis virus (rVSV)-based vaccine vectors,

118 immunostimulatory properties of recombinant vesicular stomatitis virus (rVSV)-based vaccines make th

119 Recombinant vesicular stomatitis viruses (rVSV) expressing foreign g

120 neurotropic viruses, including rabies virus, vesicular stomatitis virus, Semliki Forest virus, and he

121 EBOV, a replicating, attenuated, recombinant vesicular stomatitis virus (serotype Indiana) whose surf

122 We have used a collection of vesicular stomatitis virus strains that had been evolvin

123 RS-S) but not that of HIV-1 pseudotyped with vesicular stomatitis virus surface glycoprotein G (VSV-G

124 3 vaccine (ChAd3-EBO-Z) and the recombinant vesicular stomatitis virus vaccine (rVSVG-ZEBOV-GP) in L

125 otective efficacy of a bivalent, recombinant vesicular stomatitis virus vaccine expressing both the A

126 A replication-competent vesicular stomatitis virus vaccine expressing the Ebola

127 Remarkably, infection with vesicular stomatitis virus, vaccinia virus, and a variet

128 The live attenuated vesicular stomatitis virus-vectored Ebola vaccine rVSV-Z

129 The results highlight the ability of vesicular stomatitis virus-vectored vaccines to rapidly

130 Vesicular stomatitis virus (VSV) (a rhabdovirus) and its

131 een shown to induce G(2)/M arrest.IMPORTANCE Vesicular stomatitis virus (VSV) (a rhabdovirus) and its

132 ), only HuMxA is considered antiviral toward vesicular stomatitis virus (VSV) (a rhabdovirus).

133 t on the replication of the (-)ssRNA viruses vesicular stomatitis virus (VSV) (Rhabdoviridae family)

134 This study focuses on oncolytic vesicular stomatitis virus (VSV) against pancreatic duct

135 at intermediate pH for two vesiculoviruses, vesicular stomatitis virus (VSV) and Chandipura virus (C

136 n of herpes simplex virus type 1 (HSV-1) and vesicular stomatitis virus (VSV) and impaired the replic

137 ve immune functions following infection with vesicular stomatitis virus (VSV) and lymphocytic choriom

138 The active template for RNA synthesis for vesicular stomatitis virus (VSV) and other negative-stra

139 The L proteins of rhabdoviruses, such as vesicular stomatitis virus (VSV) and rabies virus (RABV)

140 nctional L protein of rhabdoviruses, such as vesicular stomatitis virus (VSV) and rabies virus, catal

141 The glycoproteins (G proteins) of vesicular stomatitis virus (VSV) and related rhabdovirus

142 d infections with enveloped viruses, such as Vesicular Stomatitis Virus (VSV) and Respiratory Syncyti

143 that two RNA viruses with broad host ranges, vesicular stomatitis virus (VSV) and Sindbis virus (SINV

144 h available experimental data on the DMFE of Vesicular stomatitis virus (VSV) and Tobacco etch virus

145 Oncolytic viruses such as vesicular stomatitis virus (VSV) are being considered as

146 ers, which have been employed here to purify vesicular stomatitis virus (VSV) as a model case, howeve

147 y show the specific detection of pseudotyped vesicular stomatitis virus (VSV) as a model virus on SP-

148 Using vesicular stomatitis virus (VSV) as a model, we coinfect

149 e, we describe such a strategy that utilizes vesicular stomatitis virus (VSV) as a vector for chimeri

150 re we demonstrate that mumps virus (MuV) and vesicular stomatitis virus (VSV) assemble to include CD4

151 Vesicular stomatitis virus (VSV) assembly requires conde

152 Vesicular stomatitis virus (VSV) based oncolytic viruses

153 we generate a highly infectious recombinant vesicular stomatitis virus (VSV) bearing the SARS-CoV-2

154 g ligands can be displayed on the surface of vesicular stomatitis virus (VSV) by engineering its glyc

155 on content release and infection by chimeric vesicular stomatitis virus (VSV) containing the envelope

156 Recombinant vesicular stomatitis virus (VSV) encoding the hemaggluti

157 VSVFH is a vesicular stomatitis virus (VSV) encoding the MV-Edm F a

158 ion of ACT with systemic administration of a vesicular stomatitis virus (VSV) engineered to express t

159 Vesicular stomatitis virus (VSV) exhibits a remarkably r

160 iously, we developed a replication-competent vesicular stomatitis virus (VSV) expressing a modified f

161 Using an infectious molecular clone of vesicular stomatitis virus (VSV) expressing eGFP as a ma

162 of neurotropism, we asked whether a chimeric vesicular stomatitis virus (VSV) expressing the EBOV gly

163 Experiments with recombinant vesicular stomatitis virus (VSV) expressing the EBOV Zai

164 mental vaccine for CHIKV based on a chimeric vesicular stomatitis virus (VSV) expressing the entire C

165 usly demonstrated that recombinant wild-type vesicular stomatitis virus (VSV) expressing the HBV midd

166 oV HKU5 expressing the SARS-CoV-1 spike, and vesicular stomatitis virus (VSV) expressing the SARS-CoV

167 ecotropic Moloney murine leukemia virus and vesicular stomatitis virus (VSV) G glycoproteins; and (i

168 le retroviral particles pseudotyped with the vesicular stomatitis virus (VSV) G protein with dextran-

169 y(C) binding protein 2 (PCBP2) downregulates vesicular stomatitis virus (VSV) gene expression.

170 ll interfering RNA (siRNA) screen to support vesicular stomatitis virus (VSV) growth.

171 Vesicular stomatitis virus (VSV) has been extensively st

172 Replication of vesicular stomatitis virus (VSV) has long served as a mo

173 ecause of its very low human seroprevalence, vesicular stomatitis virus (VSV) has promise as a system

174 Vesicular stomatitis virus (VSV) has shown considerable

175 Vesicular stomatitis virus (VSV) has shown substantial p

176 ectious autonomously replicating recombinant vesicular stomatitis virus (VSV) in which the glycoprote

177 itis Indiana virus (VSIV), formerly known as vesicular stomatitis virus (VSV) Indiana (VSV(IND)), is

178 regions encompassing the appendage region of vesicular stomatitis virus (VSV) Indiana serotype L prot

179 tion of Gp78 results in a robust decrease of vesicular stomatitis virus (VSV) infection and a corresp

180 Vesicular stomatitis virus (VSV) infection downregulates

181 impaired IFN production in macrophages after vesicular stomatitis virus (VSV) infection, and HIPK2-de

182 vely regulating the host IFN response during vesicular stomatitis virus (VSV) infection.

183 lso known as IFP35) as a factor required for vesicular stomatitis virus (VSV) infection.

184 of BUD13-deficient macrophages to withstand vesicular stomatitis virus (VSV) infection.

185 Vesicular stomatitis virus (VSV) is a highly cytopathic

186 Vesicular stomatitis virus (VSV) is a promising oncolyti

187 Vesicular stomatitis virus (VSV) is a promising oncolyti

188 Vesicular stomatitis virus (VSV) is a promising oncolyti

189 Recombinant vesicular stomatitis virus (VSV) is a promising therapeu

190 Vesicular stomatitis virus (VSV) is a prototype nonsegme

191 Vesicular stomatitis virus (VSV) is an archetypical memb

192 Vesicular stomatitis virus (VSV) is potent and a highly

193 Vesicular stomatitis virus (VSV) is the prototype for ne

194 polymerases since the first structure of the vesicular stomatitis virus (VSV) L protein determined in

195 electron cryomicroscopy the structure of the vesicular stomatitis virus (VSV) L protein.

196 The complex closely resembles the vesicular stomatitis virus (VSV) L-P, the one other know

197 The distribution of vesicular stomatitis virus (VSV) nucleocapsids in the cy

198 The vesicular stomatitis virus (VSV) nucleoprotein (N) assoc

199 obial molecule against infection with either vesicular stomatitis virus (VSV) or influenza was demons

200 n direct cell-to-cell transmission of either vesicular stomatitis virus (VSV) or the retrovirus MoMLV

201 Vesicular stomatitis virus (VSV) P is dimeric with an ol

202 Assembly of vesicular stomatitis virus (VSV) particles requires the

203 Upon treatment with vesicular stomatitis virus (VSV) particles, plasmacytoid

204 diated degree of shielding and the amount of vesicular stomatitis virus (VSV) particles.

205 yped HIV-1, murine leukemia virus (MLV), and vesicular stomatitis virus (VSV) particles.

206 entry, 49 constructs were incorporated onto vesicular stomatitis virus (VSV) pseudoparticles and tra

207 ent cell-to-cell fusion assays, and chimeric vesicular stomatitis virus (VSV) recombinants expressing

208 adult flies; loss of Toll-7 led to increased vesicular stomatitis virus (VSV) replication and mortali

209 function by RNAi inhibited an early stage of vesicular stomatitis virus (VSV) replication.

210 The vesicular stomatitis virus (VSV) RNA-dependent RNA polym

211 stimulated genes within the brain.IMPORTANCE Vesicular stomatitis virus (VSV) shows considerable prom

212 s (MoMLV) spread, and only minimally affects vesicular stomatitis virus (VSV) spread, to adjacent cel

213 In this study, we have engineered a chimeric vesicular stomatitis virus (VSV) that is devoid of its n

214 study, we developed a recombinant strain of vesicular stomatitis virus (VSV) that specifically targe

215 By engineering the vesicular stomatitis virus (VSV) to encode a fluorophore

216 with miRNA inhibitors in cells infected with vesicular stomatitis virus (VSV) to identify miRNAs that

217 an immunodeficiency virus type 1 (HIV-1) and vesicular stomatitis virus (VSV) to measure the neutrali

218 resses cytosolic poly(I:C), 5'ppp-dsRNA, and vesicular stomatitis virus (VSV) triggers IFN-I expressi

219 didate that utilizes a replication-defective vesicular stomatitis virus (VSV) vector backbone that la

220 nfluenza vaccine that utilizes an attenuated vesicular stomatitis virus (VSV) vector, to deliver and

221 Vesicular stomatitis virus (VSV) vectors that express he

222 rements in a simplified system, we generated vesicular stomatitis virus (VSV) virions pseudotyped wit

223 VSV-FH is a hybrid vesicular stomatitis virus (VSV) with a deletion of its

224 In this work, we developed a pseudotyped vesicular stomatitis virus (VSV) with a glycoprotein of

225 ation method is demonstrated on an RNA-based vesicular stomatitis virus (VSV) with oncolytic properti

226 e, three papers describe the pseudotyping of vesicular stomatitis virus (VSV) with the SARS-CoV-2 spi

227 the antiviral activity of interferon against vesicular stomatitis virus (VSV), a model virus that who

228 Vesicular stomatitis virus (VSV), a negative-sense RNA v

229 Work with vesicular stomatitis virus (VSV), a prototype, supports

230 aviviridae, but has no appreciable effect on vesicular stomatitis virus (VSV), a rhabdovirus.

231 We injected vesicular stomatitis virus (VSV), a transsynaptic tracer

232 K-deficient MEFs exhibit impaired control of vesicular stomatitis virus (VSV), a virus sensed by STIN

233 ks with DNA, modified vaccinia Ankara (MVA), vesicular stomatitis virus (VSV), adenovirus type 5 (Ad5

234 ly used to pseudotype glycoprotein-deficient vesicular stomatitis virus (VSV), allowing studies of BA

235 this observation, we engineered a strain of vesicular stomatitis virus (VSV), an oncolytic rhabdovir

236 activity of these ISGs against an RNA virus, vesicular stomatitis virus (VSV), and a DNA virus, murin

237 ycoproteins of Ebola virus, influenza virus, vesicular stomatitis virus (VSV), and measles virus in G

238 Here, we took a promising oncolytic virus, vesicular stomatitis virus (VSV), and tested the hypothe

239 n immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replicati

240 xpressed using the highly immunogenic vector vesicular stomatitis virus (VSV), cured mice with establ

241 infection limited the cytopathic effect from Vesicular stomatitis virus (VSV), Encephalomyocarditis v

242 ombinant rabies virus (RABV) and recombinant vesicular stomatitis virus (VSV), expressing either the

243 binant rhabdoviral vectors, rabies virus and vesicular stomatitis virus (VSV), expressing wild-type o

244 The virus studied here, vesicular stomatitis virus (VSV), like its relative, rab

245 Within 2-6 hours after infection by vesicular stomatitis virus (VSV), newly assembled VSV pa

246 al infection with influenza A virus (IAV) or vesicular stomatitis virus (VSV), respectively.

247 y, PGAM5 deficient MEFs, upon infection with vesicular stomatitis virus (VSV), revealed diminished IF

248 ted DNA aptamers against an oncolytic virus, vesicular stomatitis virus (VSV), to protect it from nAb

249 Here, a prototype RNA virus, vesicular stomatitis virus (VSV), was cultured for three

250 RdRP with those of the related rhabdovirus, vesicular stomatitis virus (VSV), we demonstrate that bo

251 cell lines and primary fibroblasts with the vesicular stomatitis virus (VSV), we detected DNA comple

252 prototype of NNS RNA virus gene expression, vesicular stomatitis virus (VSV), we determined the impo

253 By studying vesicular stomatitis virus (VSV), we identify the large

254 Working with vesicular stomatitis virus (VSV), we previously showed t

255 reporter strain of the negative-sense ssRNA vesicular stomatitis virus (VSV), we show that microinje

256 pplication of a novel viral tracer, based on vesicular stomatitis virus (VSV), which directs retrogra

257 Recombinant vesicular stomatitis virus (VSV)-based chimeric viruses

258 us (EBOV) crisis of 2013-2016, a recombinant vesicular stomatitis virus (VSV)-based EBOV vaccine was

259 In this study, we developed a vesicular stomatitis virus (VSV)-based human NoV vaccine

260 binants carrying large transgenes.IMPORTANCE Vesicular stomatitis virus (VSV)-based oncolytic viruses

261 To address these limitations, we devised a vesicular stomatitis virus (VSV)-based probe to display

262 Using a vesicular stomatitis virus (VSV)-based pseudoparticle se

263 Here, vesicular stomatitis virus (VSV)-based pseudovirions dis

264 antibody repertoire after administration of vesicular stomatitis virus (VSV)-Ebola vaccine at 3 mill

265 One of these vaccines is vesicular stomatitis virus (VSV)-EBOV, also known as rVS

266 In the vesicular stomatitis virus (VSV)-induced encephalitis mo

267 In vesicular stomatitis virus (VSV)-infected Huh7 cells, th

268 -like helicase (RLH) signaling contribute to vesicular stomatitis virus (VSV)-mediated triggering of

269 ue of Blood, Shen et al demonstrate that the vesicular stomatitis virus (VSV)-murine interferon beta

270 ve and cells that are resistant to oncolytic vesicular stomatitis virus (VSV).

271 h influenza virus, West Nile virus (WNV), or vesicular stomatitis virus (VSV).

272 ll carcinoma (HNSCC) lines from oncolysis by vesicular stomatitis virus (VSV).

273 mouse model of prostate cancer infected with vesicular stomatitis virus (VSV).

274 t cell targets for the matrix (M) protein of vesicular stomatitis virus (VSV).

275 NS RNA viruses comes largely from studies of vesicular stomatitis virus (VSV).

276 r pattern was observed for the IFN-sensitive vesicular stomatitis virus (VSV).

277 al infection by the neurotropic rhabdovirus, vesicular stomatitis virus (VSV).

278 and it inhibits the replication of HSV-1 and vesicular stomatitis virus (VSV).

279 cytopathic viruses, such as the neurotropic vesicular stomatitis virus (VSV).

280 ferent turns, as is observed for the related Vesicular stomatitis virus (VSV).

281 s virus (LCMV); influenza A virus (IAV); and vesicular stomatitis virus (VSV).

282 ite-directed mutagenesis of the L protein of vesicular stomatitis virus (VSV, a prototypic NNS RNA vi

283 hanisms by which the transmembrane domain of vesicular stomatitis virus (VSV-TMD) promotes both initi

284 Here we test replication-competent vesicular stomatitis viruses (VSV) on 19 primary human m

285 RhIVs are based on vesicular stomatitis viruses (VSV), but viral entry is m

286 Here we show that both RNA (vesicular stomatitis virus [VSV]) and DNA (cytomegalovir

287 se in early endosomes (SFV, SINV, CHIKV, and vesicular stomatitis virus [VSV]), while viruses that fu

288 eins via replication incompetent recombinant vesicular stomatitis viruses (VSVs) and human adenovirus

289 We are developing oncolytic vesicular stomatitis viruses (VSVs) for systemic treatme

290 cell lines to infection by the nonretrovirus vesicular stomatitis virus were indistinguishable.

291 sed by two TLR3-dependent viruses (HSV-1 and vesicular stomatitis virus) were high in fibroblasts fro

292 starting with poliovirus and then moving to vesicular stomatitis virus, where he discovered a virion

293 Chimeric vesicular stomatitis viruses with the EBOV glycoprotein

294 for rapid expanded access to the recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV

295 Recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV

296 2503202) evaluated the safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope gl

297 , lot consistency, and safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope gl

298 safety and immunogenicity of the recombinant vesicular stomatitis virus-Zaire Ebola virus envelope gl

299 for rapid expanded access to the recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine (rV

300 uencing backed up the use of the recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine in